GlobeNewsWire
20 Aug 2026, 10:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Avricore Health's subsidiary, HealthTab, has signed a multi-year collaboration agreement with Abbott to distribute point-of-care testing products in the UK. — Partnering with a global leader like Abbott provides critical validation and a scalable distribution channel for a small-cap company like Avricore.
+0.80The agreement specifically enables the distribution of Abbott’s Afinion™ 2 Analyzer in NHS-linked pharmacies for HbA1c and lipid profile testing. — Securing access to the NHS-linked pharmacy network provides a clear, regulated path to revenue and market penetration in the UK.
+0.50The collaboration establishes a structured framework for the continued expansion of point-of-care testing across community pharmacies. — While promising for long-term growth, the specific terms and timeline for this expansion remain undefined.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company achieved its most significant milestone to date by securing a collaboration agreement with Abbott to distribute PoCT products in the UK.
The company is expanding its distribution network and market reach for its Afinion 2 Analyzer via a new partnership.
[mutual] Avricore Health's subsidiary HealthTab entered a collaboration agreement to supply and distribute Abbott's point-of-care testing products in the UK.
[a_to_b] Abbott supplies point-of-care testing products, specifically the Afinion 2 Analyzer, to Avricore Health's HealthTab platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
7h ago
